Market Intelligence

Access the latest earnings reports, market analysis, hot topics, and individual stock insights

Report Categories

View All

Recent Articles

View All
Is Pamt Corp Pamt Stock Ready To Rally Price At 9.53 Down 2.36 20260410 Will 4D Fdmt Stock Hit Record Highs Price At 9.48 Down 3.95 20260402 What Are The Biggest Risks For General Gd Stock Price At 338.50 Up 1.00 20260413 Is Peraso Prso Stock Overvalued Relative To Peers Price At 0.99 Down 1.20 20260409 Will Mge Energy Mgee Stock Recover Soon Price At 78.68 Down 0.16 20260406 Is X4 Pharmaceuticals XFOR stock a solid choice for investors Q4 2025 Earnings Beat Estimates Why Currenc CURR is a smarter play than most realize Institutional Demand 20260508 What is dragging Innovative Eyewear LUCY stock lower Q4 2025 EPS Exceeds Expectations CeriBell CBLL Future Plans CeriBell Inc beats EPS estimates by 144 on narrower loss Vanguard Group VB Is Vanguard SmallCap Index Admiral VSMAX a Viable SmallCap Mutual Fund Selection for 2026 Why CHS Series 4 CHSCL might surprise investors this quarter Stalls 20260511 American Tower Corporation AMT Outperforms Broader Market Rally Ahead of Q1 2026 Earnings Release CRC Cal Resource Q4 2025 revenue grows 151 percent year over year but EPS miss pushes stock down 072 percent DYOR Insight DPII points to accelerating AI client adoption as its primary future revenue growth driver The Charles Schwab Corporation SCHW Delivers Strong Q1 2026 Earnings Beat Amid Mixed Brokerage Sector Results AVD Am Vanguard posts drastically wider Q3 2025 loss versus analyst estimates on unforeseen cost pressures TONX TON Q3 2025 loss per share narrows far more than expected stock falls 146 percent today Replimune Group REPL Stock Market Pressure Analysis Smart Money Exits 20260427 Why trivago TRVG is a smarter play than most realize Soars 20260508 Trumps Golden Dome Missile Defense System Estimated at 12 Trillion Seven Times Initial Estimate NextGeneration Heirs Value Continuity in Wealth Advisory Relationships UBS Study Finds Traders Flip Expectations Fed Rate Hike Back in Play After Inflation Surge Consumer Sentiment Falls to New Low in Early May Amid Surging Gas Prices From Iran Conflict Graphic GPK Stock Consolidating at 966 Next Move Ahead 20260518 Trump Endorses Paxton Over Cornyn in Texas Senate Runoff Escalating IntraParty Battle Atossa ATOS Slips 134 Testing 455 Support 20260518 USA TODAY TDAY Q1 2026 Earnings Why the Beat Matters Ola Electric Reports Narrowed Q4 Loss Ahead of New EV Model Launches Valley VLYPO Tops Q1 2026 Expectations with EPS of 029 Easterly Gov DEA Q1 2026 Profit Slips to 003 Misses Analyst Forecasts Dermata DRMA Q1 2026 Earnings 048 EPS Surges Past 054 Estimates Iran Signals Potential Strait of Hormuz Reopening 30 Days PostPeace Deal Nikkei Reports ProfitTaking Strategy Portfolio Manager Trims Stock After 80 Surge Since April Market Rotation Away from Blue Chips Signals Potential Shift in Investor Sentiment Sterlite Technologies Gains 5 as Subsidiary Secures 11 Billion Hyperscaler AI Data Center Contract Nvidias Earnings Reveal 200 Billion Edge Computing Opportunity Amid China Market Concession MITK Q1 2026 Earnings EPS Beat Sent Shares Higher Amid Strong Operational Execution SITM Q1 2026 Earnings EPS Surges Past Estimates with 22 Beat MHLA Q3 2024 Earnings Underlying Company Reports Negative EPS No Revenue Data Available KLXE Q1 2026 Earnings NarrowerThanExpected Loss Fails to Stem Stock Decline Bioventus BVS Q1 2026 Earnings Strong EPS Beat Amidst Market Skepticism Valley National Bancorp Preferred Stock VLYPO Holds Steady Near 2512 Key Support and Resistance in Focus LZ Technology Holdings LZMH Surges 85 as Bullish Momentum Builds Near Resistance Medicus Pharma Ltd MDCX Edges Higher Testing Key Resistance at 032 Decent Hldg DXST Stock Stability Check 560 20260415 DocGo DCGO Stock Volatility Q4 2025 Profit Disappoints Stantec STN beats Q4 estimates by 2 but stock drops 4 as investors weigh margin pressures How Entergy EAI stacks up against analyst expectations Ticks Higher 20260508 What Magnera Corporation MAGN has done differently this quarter Q1 2026 Profit Disappoints RARE Ultragenyx Pharmaceutical revenue surges 20 on new drug demand but wider losses disappoint investors